Tags : NGM313

Merck Exercises its Option to License NGM’s NGM313 (MK-3655) for

Shots:  NGM to receive $20M as total deal value with anoption to participate in P-III trial of MK-3655 with equal cost and revenue sharing. Merck to get exclusive worldwide rights to develop and commercialize NGM’s NGM313 (currently MK-3655) If the option is not exercised by NGM, it will receive milestones and royalties on sales of […]Read More